Renalytix PLC on Wednesday hailed the results of a new independent review, which it said demonstrated the utility of KidneyIntelX in diagnosing patients with kidney disease and diabetes.

The London-based kidney health-focused diagnostics company noted the publication of new real-world evidence case studies published in the peer-reviewed journal, Diabetic Nephropathy, entitled: ‘The Need for Risk Stratification in Type 2 Diabetes and Chronic Kidney Disease: Proposed Clinical Value of KidneyIntelX’.

Several themes permeated the review, which showed that lack of kidney disease education and patient awareness in the primary care setting is a real barrier to care management, and also that a significant opportunity exists for type two diabetic patients to learn about chronic kidney disease management.

‘This independent review reinforces the importance of KidneyIntelX early prognosis in patients with kidney disease and type 2 diabetes. These utility results were well represented in ’real-time’ with the reported case studies and the introduction of the KidneyIntelX bioprognosis supporting clinical decision making and care optimization across a spectrum of kidney event risk,’ said Chief Medical Officer Michael Donovan.

Renalytix shares were trading 3.8% higher at 96.50 pence each in London on Wednesday morning.

Copyright 2023 Alliance News Ltd. All Rights Reserved.